ClinicalTrials.gg

Program

Istaroxime

Also written as “istaroxime”.

Its studies are mostly in Heart Failure · Shock, Cardiogenic, led by 5 companies.

Furthest: phase 3, since Jul 9, 20158 company-led studies, 2 open or runningNext primary completion: Dec 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Windtree Therapeutics31 open or runningphase 2since Jul 9, 2015Jul 9, 2015none ahead
Debiopharm20 open or runningphase 2since Feb 5, 2009Feb 5, 2009none ahead
Lee's Pharmaceutical10 open or runningphase 1since Jun 17, 2015Jun 17, 2015none ahead
Seismic Pharmaceuticals Operations11 open or runningphase 3since May 1, 2026May 1, 2026Dec 2028phase 3 · NCT07583446
sigma-tau i.f.r.10 open or runningphase 2since Feb 5, 2008Feb 5, 2008none ahead

Also a collaborator on its studies: cvie-therapeutics-co-ltd, momentum-research-inc and mds-pharma-services.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 5, 2008First study: phase 2 study in Heart FailureNew to sigma-tau i.f.r.sigma-tau i.f.r. · NCT00616161 · 120 enrolled
  2. Feb 5, 2009Debiopharm's first study: phase 2 study in Heart FailureNew to DebiopharmDebiopharm · NCT00838253
  3. Mar 24, 2009Phase 1 study in Heart FailureDebiopharm · NCT00869115
  4. Jun 17, 2015Lee's Pharmaceutical's first study: phase 1 study in HealthyNew to Lee's PharmaceuticalLee's Pharmaceutical · NCT02477449 · 32 enrolled · China
  5. Jul 9, 2015Windtree Therapeutics's first study: phase 2 study in Acute Decompensated Heart FailureNew to Windtree TherapeuticsWindtree Therapeutics · NCT02617446 · 120 enrolled · China, Italy
  6. Mar 24, 2020Phase 2 study in Shock, CardiogenicWindtree Therapeutics · NCT04325035 · 90 enrolled · United States, Argentina, Italy and more
  7. Jul 26, 2023Phase 2 study in Shock, CardiogenicWindtree Therapeutics · NCT05975021 · 20 enrolled · United States, Argentina, Israel and more
  8. May 1, 2026Seismic Pharmaceuticals Operations's first study: phase 3 study in Shock, CardiogenicNew to Seismic Pharmaceuticals OperationsSeismic Pharmaceuticals Operations · NCT07583446 · 600 planned · Armenia

Ahead

  1. Dec 2028Primary completion: phase 3 study in Shock, CardiogenicSeismic Pharmaceuticals Operations · NCT07583446

TargetBeta

“Sodium/potassium-transporting ATPase inhibitor; Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 activator”ChEMBL 37, by rule

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07583446Shock, Cardiogenic · Armenia3RecruitingSeismic Pharmaceuticals OperationsDec 2028600
NCT05975021Shock, Cardiogenic · United States, Argentina, Israel and more2Active, not recruitingWindtree TherapeuticsJul 28, 202520
NCT04325035Shock, Cardiogenic · United States, Argentina, Italy and more2CompletedWindtree TherapeuticsSep 26, 202490
NCT02617446Acute Decompensated Heart Failure · China, Italy2CompletedWindtree TherapeuticsAug 14, 2018120
NCT02477449Healthy · China1CompletedLee's PharmaceuticalOct 201532
NCT00869115Heart Failure1WithdrawnDebiopharm0
NCT00838253Heart Failure2WithdrawnDebiopharm0
NCT00616161Heart Failure2Completedsigma-tau i.f.r.Jul 2007120

How it is read

Names in the registry

  • “Istaroxime”, 13 entries
  • “istaroxime”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.